ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
Looking ahead, ALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann said that its multiple ongoing clinical studies are set to position the company for near- and long-term success.
GlobalData on MSN6mon
Greenridge intends to acquire ALX ResourcesALX CEO Warren Stanyer will join Greenridge as president and director. The merger is also expected to yield significant cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback